A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis.
In a double-blind crossover trial of pseudoephedrine 60 mg and triprolidine 2.5 mg, alone and in combination, on 40 volunteers suffering from allergic rhinitis, both drugs were found superior to placebo in reducing the effects of allergic rhinitis and were of equal efficacy. The combination tablet was consistently better than either drug in several of the assessments and was the treatment which the subjects, as a whole, preferred. Side effects were not a problem with any of the medications.
D000328:Adult; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004809:Ephedrine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors; D014311:Triprolidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D010919:Placebos; D011725:Pyridines; D014311:Triprolidine; D004809:Ephedrine